Mandate

Vinge advises Biotage in connection with its acquisition of Astrea from KKR’s life science platform Gamma

Vinge advises Biotage AB (publ) (“Biotage”) in connection with its acquisition of Astrea Bioseparations (“Astrea”), a high-growth chromatography solutions provider from Gamma Biosciences (“Gamma”), a life sciences tools platform created and controlled by KKR.

The acquisition extends Biotage’s chromatography franchise into the higher-growth and larger bioprocessing segment, while also increasing exposure to biologics and advanced therapeutic customers.

The purchase price will be paid in new ordinary shares in Biotage, entailing that the KKR-controlled Gamma is expected to become the largest shareholder in Biotage, with an ownership of approximately 17 percent.

The transaction is subject to shareholder approval by the general meeting of Biotage and customary closing conditions, including approvals from the UK authorities.

Vinge’s team consisted of Matthias Pannier, Karl Klackenberg, Linus Adolfsson, Sebastian Saadieh, Elis Allmark (M&A), Dain Hård Nevonen, William Kåge, Joel Magnusson, Anna Svensson, Gabriel Chabo (Capital Markets), Sebastian Örndahl (Anti-trust), Sara Dahlros Sköld and Julia Hagelberg (VDR).

Related

Vinge advises Workday, Inc. on its $1.1 billion acquisition of Sana Labs

Vinge, together with Orrick Herrington & Sutcliffe, has advised Workday, Inc. (NASDAQ: WDAY) (“Workday”) on its acquisition of all shares in Sana Labs AB.
September 16, 2025

Vinge advises on the sale of ArmaTech to Defensor Group

Vinge has advised on the sale of ArmaTech i Kungsbacka AB (“ArmaTech”) to the newly formed defence group Defensor Group AB (“Defensor”).
September 16, 2025

Vinge advisor in connection with Klarna's IPO on the New York Stock Exchange

Vinge, together with Latham & Watkins, acted as advisor to bookrunners and managers in connection with the listing of Klarna, the global digital bank and provider of flexible payment solutions, on the New York Stock Exchange.
September 15, 2025